Trial · NCT05918978
Results by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 45
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With TEAEs, TESAEs and TEAESIs | Efgartigimod-Efgartigimod | TEAEs | 13 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Placebo-Efgartigimod | TEAEs | 12 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Efgartigimod-Efgartigimod | TESAEs | 0 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Placebo-Efgartigimod | TESAEs | 0 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Efgartigimod-Efgartigimod | TEAESIs | 7 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Placebo-Efgartigimod | TEAESIs | 5 | Participants | |
| Change From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version) | Efgartigimod-Efgartigimod | Week 24 | 13.608 | Standard Deviation 29.7026 | score on a scale |
| Change From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version) | Placebo-Efgartigimod | Week 24 | 8.447 | Standard Deviation 18.1170 | score on a scale |
| Change From Baseline to Weeks 24 and 48 in the COMPASS 31 (2-week Recall Version) | Efgartigimod-Efgartigimod | Week 48 | 1.780 | score on a scale | |
| Change From Baseline to Weeks 24 and 48 in the MaPS | Efgartigimod-Efgartigimod | Week 24 | -0.8 | Standard Deviation 22.02 | score on a scale |
| Change From Baseline to Weeks 24 and 48 in the MaPS | Placebo-Efgartigimod | Week 24 | 10.3 | Standard Deviation 24.95 | score on a scale |
| Change From Baseline to Weeks 24 and 48 in the MaPS | Efgartigimod-Efgartigimod | Week 48 | -17.0 | score on a scale | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 24, 1-week recall | 12.5 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Placebo-Efgartigimod | Week 24, 1-week recall | 0 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 24, 2-week recall | 12.5 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Placebo-Efgartigimod | Week 24, 2-week recall | 0 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 48, 1-week recall | 25.0 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Placebo-Efgartigimod | Week 48, 1-week recall | 0 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 48, 2-week recall | 25.0 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Weeks 24 and 48 | Placebo-Efgartigimod | Week 48, 2-week recall | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05918978/results